Status:
RECRUITING
Oxytocin Maintenance Infusion in Labouring Women Undergoing Cesarean Delivery: an Up-down Sequential Allocation Study
Lead Sponsor:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Conditions:
Postpartum Hemorrhage
Eligibility:
FEMALE
18-50 years
Phase:
NA
Brief Summary
This study is designed to determine the minimal effective oxytocin maintenance infusion required in labouring women undergoing cesarean delivery to achieve the best effect. Oxytocin is a drug that is ...
Detailed Description
This study will be conducted as a prospective, double blinded clinical trial (patient, anesthesiologist and obstetrician blinded to the oxytocin dose), in an up-down sequential allocation fashion. The...
Eligibility Criteria
Inclusion
- • All patients with induced or augmented labour undergoing cesarean delivery under neuraxial anesthesia (at least 3 hours of prior exposure to oxytocin during labour)
Exclusion
- All patients who refuse to give written informed consent
- All patients who declare allergy or hypersensitivity to oxytocin
- A history of hypertension and/or severe cardiac disease(s)
- All patients who have contraindications for neuraxial anesthesia
- All patients who will be converted to general anesthesia intraoperatively
- All patients with placenta previa and multiple gestation
Key Trial Info
Start Date :
August 17 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05290129
Start Date
August 17 2022
End Date
December 1 2025
Last Update
June 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G1X5